Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for cancers and autoimmune diseases. The company leverages its proprietary ARTEMIS T Cell Receptor Platform to engineer T cells designed to overcome limitations of traditional CAR-T therapies, such as high toxicity and cost. Its lead product candidate, EB103, is being advanced in conjunction with CF33-CD19t, with manufacturing and R&D support provided by Eureka Therapeutics under a Services Agreement.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001213900-26-029357 | EDGAR | 93K words |
| 2024-09-27 | 2024-06-30 | 0001213900-24-082374 | EDGAR | 111K words |
| 2023-03-14 | 2022-12-31 | 0001575872-23-000353 | EDGAR | 44K words |
| 2022-03-29 | 2021-12-31 | 0001410578-22-000598 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001213900-26-089215 | EDGAR | 22K words |
| 2025-11-12 | 2025-09-30 | 0001213900-25-109198 | EDGAR | 25K words |
| 2025-08-12 | 2025-06-30 | 0001213900-25-074567 | EDGAR | 26K words |
| 2025-05-14 | 2025-03-31 | 0001213900-25-043365 | EDGAR | 23K words |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098450 | EDGAR | 29K words |
| 2024-05-15 | 2024-03-31 | 0001213900-24-043126 | EDGAR | 31K words |
| 2024-02-14 | 2023-12-31 | 0001213900-24-014191 | EDGAR | 28K words |
| 2023-11-20 | 2023-09-30 | 0001213900-23-088827 | EDGAR | 25K words |
| 2023-08-01 | 2023-06-30 | 0001213900-23-061563 | EDGAR | 25K words |
| 2023-05-18 | 2023-03-31 | 0001575872-23-000781 | EDGAR | 21K words |
| 2022-11-14 | 2022-09-30 | 0001575872-22-001112 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001410578-22-002124 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001213900-26-098123 | EDGAR | 1K words |
| 2026-08-21 | 0001213900-26-092657 | EDGAR | 1K words |
| 2026-01-13 | 0001213900-26-003998 | EDGAR | 1K words |
| 2026-01-06 | 0001213900-26-001777 | EDGAR | 1K words |
| 2025-12-04 | 0001213900-25-118097 | EDGAR | 1K words |
| 2025-11-06 | 0001213900-25-107249 | EDGAR | 1K words |
| 2025-09-29 | 0001213900-25-093197 | EDGAR | 1K words |
| 2025-09-26 | 0001213900-25-092471 | EDGAR | 1K words |
| 2025-08-07 | 0001213900-25-072746 | EDGAR | 1K words |
| 2025-06-05 | 0001213900-25-051361 | EDGAR | 1K words |
101 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001844417 |
| Ticker | ESLA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.estrellabio.com |
| Listed | 2023-10-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ESLA (~200 tokens, structured JSON with cryptographic provenance)